Evaluación:
(not yet rated) | Resumen | Whether monoclonal antibodies are able to neutralise SARS-CoV-2 variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralise authentic SARS-CoV-2 including variant B.1.1.7 (Alpha) but variants B.1.351 (Beta) and P.2 (Zeta) were resistant against bamlanivimab and partially to casirivimab. |
|---|---|
| Procedencia del autor |
| Texto completo |
|---|
| Palabras clave | SARS-CoV-2, corona virus, monoclonal antibodies, bamlanivimab, casirivimab, imdevinab |
|---|
| Tipo de documento |
|---|
| Publicado en el sitio | 2021-07-30 18:47:02 |
|---|
(aún no hay comentarios disponibles para este recurso)
Crear cuenta
Comentarios